GeNeuro SA (GNRRF)
- Business Wire
GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results, Provides a Business Update and Cash Position as of December 31, 2021
GENEVA, January 27, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update.
- Business Wire
Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
GENEVA, December 20, 2021--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the "The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases" additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnersh
- Business Wire
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
GENEVA, December 13, 2021--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of 6.7 million Swiss francs (€6
